Available IPD datapackage for study 'A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy'

Name: Available IPD datapackage for study 'A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy'
Creator: Vivli
Published: 2025-01-06 16:17:12
License: 暂无描述

DataCite Commons2025-01-06 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/dataPackages/PR00005170.0

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate (gland that makes fluid that aids movement of sperm) cancer (HRPC).

提供机构：

Vivli

创建时间：

2023-06-02